Monsanto Company announced today that the U.S. Food and Drug Administration (FDA) has approved full production of POSILAC® bovine somatotropin (bST) at its manufacturing facility in
“Full FDA approval of our
Product release will be conducted in three waves over the next couple of months, explains Holloway. The first wave to receive additional product will be existing customers with unmet demand. The second wave will be producers who are already on the waiting list. And the final wave of customers to receive product will be new customers who have yet to call in to be placed on the waiting list.
To be placed on the waiting list, or to find out more about the Posilac supply, call Monsanto’s
Monsanto employs over 200 people full-time at the